Clinical Trials

80 enrolled

Breast Neoplasms, Neoplasms

NCT04158258 2026-02-12

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

2,907 enrolled

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

86 enrolled

Breast Neoplasms

NCT03199300 2025-12-11

InvestiCAT

20 enrolled

Tumor-Agnostic

Neoplasms, Second Primary

NCT06663787 2025-11-28

HER2 CR

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT03738553 2025-10-29

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

13 enrolled

HER2-positive Breast Cancer

NCT07009600 2025-06-06

Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

124 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02771795 2024-02-02

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Terminated

538 enrolled 9 charts

Breast Neoplasms, Neoplasms

NCT06021379 2023-10-31

AryoTrust® (Trastuzumab) Safety Study

597 enrolled

Breast Neoplasms

NCT05912062 2023-09-29

BiOnHER

80 enrolled

Breast Neoplasms, Neoplasms

NCT05931042 2023-07-05

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

1,209 enrolled

HER2+ Breast Cancer

NCT05030519 2022-03-02

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

50 enrolled

Breast Neoplasms

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

120 enrolled

Feasibility

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting

300 enrolled

Breast Neoplasms

NCT03521245 2021-09-14

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

40 enrolled

Breast Neoplasms

NCT04962425 2021-07-15

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

240 enrolled

Breast Neoplasms, Cardiotoxicity

NCT04961307 2021-07-14

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

30 enrolled

Breast Neoplasms, Cardiotoxicity

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT04609540 2020-12-16

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

200 enrolled

Breast Neoplasms

NCT01959386 2020-03-03

HerSCin

1,006 enrolled

Breast Neoplasms

NCT00833963 2019-05-16

MotHER

20 enrolled

Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

300 enrolled

Breast Cancer Organoids

NCT01839500 2018-03-29

EVIDENCE

1,600 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00875238 2018-02-19

PACE in BC

133 enrolled

Breast Neoplasms, Cardiotoxicity

NCT01152606 2018-01-25

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

3,942 enrolled

Breast Neoplasms

NCT03390608 2018-01-04

Prognostic and Predictive Factors for Small Breast Tumors

35,002 enrolled

Breast Neoplasms

NCT00755313 2017-11-24

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

81 enrolled

Breast Neoplasms, Fatigue, Neurotoxicity Syndromes

NCT01187381 2017-10-20

HERODOT

Terminated

250 enrolled 12 charts

Breast Neoplasms

NCT01480674 2017-08-16

An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

160 enrolled 13 charts

Breast Neoplasms

NCT03024450 2017-01-24

Trastuzumab Based Therapy in HER2 Positive AGC

98 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02656589 2016-10-13

microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

300 enrolled

Breast Neoplasms

NCT02062983 2016-05-13

Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

Suspended

50 enrolled

Breast Neoplasms

NCT02658461 2016-04-29

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

36 enrolled 15 charts

Breast Neoplasms

NCT00968682 2014-12-31

CADY Study ICORG 08-01

480 enrolled

Breast Neoplasms, Cardiotoxicity

NCT01077648 2014-05-26

Brain Metastasis in Breast Cancer Patients